Skip to main content
Top
Published in: Journal of Cachexia, Sarcopenia and Muscle 3/2013

01-09-2013 | Review

Cachexia as a major public health problem: frequent, costly, and deadly

Authors: Jerneja Farkas, Stephan von Haehling, Kamyar Kalantar-Zadeh, John E. Morley, Stefan D. Anker, Mitja Lainscak

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 3/2013

Login to get access

Abstract

Perception of healthy body size and composition differs considerably across the globe, ethnic groups, cultures, and even inside medical community. Although the concept of ideal body weight has evolved over the past decades, the observation that weight loss can have more deleterious effects within a short-term period than weight gain has remained rather consistent. Weight loss, as a prelude to cachexia, occurs frequently in a variety of disease states and meets the requirements of a global public health problem. Consequently, interventions to prevent and control chronic diseases require a comprehensive approach that targets a population as a whole and includes both prevention and treatment strategies. Around the globe, cachexia awareness campaigns and expanding the current public health priorities to highlight the cachexia magnitude and areas of interventions is necessary. Simultaneously, scientific efforts should provide us with more reliable estimates of body wasting and cachexia as well as pathophysiology of cachexia-associated death. As certain proportion of patients will, irrespective of preventive measures, eventually develop cachexia, a quest for effective remedy remains vital.
Literature
1.
go back to reference von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5.CrossRef von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5.CrossRef
2.
go back to reference Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101:8–10.CrossRef Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101:8–10.CrossRef
3.
go back to reference Onwuamaegbu ME, Henein M, Coats AJ. Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J. 2004;80:642–9.PubMedCrossRef Onwuamaegbu ME, Henein M, Coats AJ. Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J. 2004;80:642–9.PubMedCrossRef
4.
go back to reference von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121:227–52.CrossRef von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121:227–52.CrossRef
5.
go back to reference Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011;2:9–25.PubMedCrossRef Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011;2:9–25.PubMedCrossRef
6.
go back to reference World Health Organization. The global burden of disease, 2004 update. Geneva: World Health Organization; 2008. World Health Organization. The global burden of disease, 2004 update. Geneva: World Health Organization; 2008.
7.
8.
go back to reference Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.PubMed Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.PubMed
9.
go back to reference Tan BHL, Fearon KCH. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11:400–7.PubMedCrossRef Tan BHL, Fearon KCH. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11:400–7.PubMedCrossRef
10.
go back to reference Evans WJ, Morley JE, Argile’s J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef Evans WJ, Morley JE, Argile’s J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef
11.
go back to reference von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010;1:187–94.CrossRef von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010;1:187–94.CrossRef
12.
go back to reference Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet. 2008;371:915–22.PubMedCrossRef Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet. 2008;371:915–22.PubMedCrossRef
13.
go back to reference Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, et al. Predominance of heart failure in the Heart of Soweto Study cohort. Emerging challenges for urban African communities. Circulation. 2008;118:2360–7.PubMedCrossRef Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, et al. Predominance of heart failure in the Heart of Soweto Study cohort. Emerging challenges for urban African communities. Circulation. 2008;118:2360–7.PubMedCrossRef
14.
go back to reference Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, Selum W, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis. 2010;4:e688.PubMedCrossRef Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, Selum W, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis. 2010;4:e688.PubMedCrossRef
15.
go back to reference Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Fanelli FR. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42:31–41.PubMedCrossRef Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Fanelli FR. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42:31–41.PubMedCrossRef
16.
go back to reference Detels R, Breslow L. Current scope and concerns in public health. In: Detels R, McEwen J, Beaglehole R, Tanaka H, editors. Oxford textbook of public health. 4th ed. New York: Oxford University Press; 2004. Detels R, Breslow L. Current scope and concerns in public health. In: Detels R, McEwen J, Beaglehole R, Tanaka H, editors. Oxford textbook of public health. 4th ed. New York: Oxford University Press; 2004.
17.
go back to reference Saaddine JB, Narayan KM, Vinicor F. Vision loss: a public health problem? Ophthalmology. 2003;110:253–4.PubMedCrossRef Saaddine JB, Narayan KM, Vinicor F. Vision loss: a public health problem? Ophthalmology. 2003;110:253–4.PubMedCrossRef
18.
go back to reference Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3:A57.PubMed Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3:A57.PubMed
19.
go back to reference Verweij M, Dawson A. The meaning of “public” in public health. In: Dawson A, Verweij M, editors. Ethics, prevention, and public health. Oxford: Oxford University Press; 2007. Verweij M, Dawson A. The meaning of “public” in public health. In: Dawson A, Verweij M, editors. Ethics, prevention, and public health. Oxford: Oxford University Press; 2007.
20.
go back to reference World Health Organization. Global status report on non-communicable diseases 2010. Geneva: World Health Organization; 2011. World Health Organization. Global status report on non-communicable diseases 2010. Geneva: World Health Organization; 2011.
21.
go back to reference Strong K, Mathers CD, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet. 2005;366:1578–82.PubMedCrossRef Strong K, Mathers CD, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet. 2005;366:1578–82.PubMedCrossRef
22.
go back to reference Kapiga S. Commentary: non-communicable diseases in sub-Saharan Africa: a new global health priority and opportunity. Int J Epidemiol. 2011;40:902–3.PubMedCrossRef Kapiga S. Commentary: non-communicable diseases in sub-Saharan Africa: a new global health priority and opportunity. Int J Epidemiol. 2011;40:902–3.PubMedCrossRef
23.
go back to reference Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94:16–26.PubMedCrossRef Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94:16–26.PubMedCrossRef
24.
go back to reference Puska P. Non-communicable diseases - neglected diseases in global health work? Eur J Public Health. 2011;21:269–70.PubMedCrossRef Puska P. Non-communicable diseases - neglected diseases in global health work? Eur J Public Health. 2011;21:269–70.PubMedCrossRef
25.
go back to reference World Health Organization. Preventing chronic diseases: a vital investment. Geneva: World Health Organization; 2005. World Health Organization. Preventing chronic diseases: a vital investment. Geneva: World Health Organization; 2005.
26.
go back to reference Popkin BM, Adair LS, Ng SW. Now and then: the global nutrition transition: the pandemic of obesity in developing countries. Nutr Rev. 2012;70:3–21.PubMedCrossRef Popkin BM, Adair LS, Ng SW. Now and then: the global nutrition transition: the pandemic of obesity in developing countries. Nutr Rev. 2012;70:3–21.PubMedCrossRef
27.
go back to reference Finucane MM, Stevens GA, Cowan MJ, et al. Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.PubMedCrossRef Finucane MM, Stevens GA, Cowan MJ, et al. Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.PubMedCrossRef
28.
go back to reference Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalence. Popul Health Metr. 2012;10:22.PubMedCrossRef Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalence. Popul Health Metr. 2012;10:22.PubMedCrossRef
29.
go back to reference World Health Organization. Non-communicable diseases country profiles 2011. Geneva: World Health Organization; 2011. World Health Organization. Non-communicable diseases country profiles 2011. Geneva: World Health Organization; 2011.
30.
go back to reference Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007;8:191–6.CrossRef Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007;8:191–6.CrossRef
31.
32.
go back to reference Yusuf S, HAwken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.PubMedCrossRef Yusuf S, HAwken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.PubMedCrossRef
33.
go back to reference Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMedCrossRef Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMedCrossRef
34.
go back to reference Coats AJS, Srinivasan V, Surendran J, Chiramana H, Vangipuram SRKG, Bhatt NN, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2:201–7.CrossRef Coats AJS, Srinivasan V, Surendran J, Chiramana H, Vangipuram SRKG, Bhatt NN, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2:201–7.CrossRef
35.
go back to reference Patel SP, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4:19–29. Patel SP, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4:19–29.
36.
go back to reference Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078–88.PubMedCrossRef Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078–88.PubMedCrossRef
37.
go back to reference Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10:433–42.PubMedCrossRef Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10:433–42.PubMedCrossRef
38.
go back to reference Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox: facts and numbers. J Cachexia Sarcopenia Muscle. 2012;3:1–4.PubMedCrossRef Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox: facts and numbers. J Cachexia Sarcopenia Muscle. 2012;3:1–4.PubMedCrossRef
39.
go back to reference World Health Organization. 2008–2013 Action plan for the Global strategy for the prevention and control of non-communicable diseases. Geneva: World Health Organization; 2008. World Health Organization. 2008–2013 Action plan for the Global strategy for the prevention and control of non-communicable diseases. Geneva: World Health Organization; 2008.
Metadata
Title
Cachexia as a major public health problem: frequent, costly, and deadly
Authors
Jerneja Farkas
Stephan von Haehling
Kamyar Kalantar-Zadeh
John E. Morley
Stefan D. Anker
Mitja Lainscak
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cachexia, Sarcopenia and Muscle / Issue 3/2013
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-013-0105-y

Other articles of this Issue 3/2013

Journal of Cachexia, Sarcopenia and Muscle 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.